FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * SCHUMACHER RICHARD T   2. Issuer Name and Ticker or Trading Symbol PRESSURE BIOSCIENCES INC [PBIO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) CEO (Last) (First) (Middle) 130 LAKE RIDGE DRIVE 3. Date of Earliest Transaction (Month/Day/Year) 04/30/2012 (Street) TAUNTON, MA US 02780 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 04/30/2012   C   93,786 A $ 0.8025 462,152 D   Common Stock 04/30/2012   J(3)   4,652 A $ 0.8025 466,804 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Series C Convertible Preferred Stock

$ 0.8025

04/30/2012

C

5,018

04/08/2011

(1)

Common Stock

93,786

(2)

0

D

Common Stock Purchase Warrant

$ 2.38

04/30/2012

C

50,180

04/08/2011

04/08/2014

Common Stock

50,180

(2)

0

D

Common Stock Purchase Warrant

$ 0.74

04/30/2012

C

46,894

04/05/2012

04/05/2017

Common Stock

46,894

(2)

46,894

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
SCHUMACHER RICHARD T 130 LAKE RIDGE DRIVE TAUNTON, MA US 02780	X		CEO

Signatures

Richard T Schumacher		05/02/2012
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The Series C Convertible Preferred Stock has no expiration date.
(2)	Pursuant to a certain Securities Purchase Agreement, dated April 8, 2011, among the Company, the Reporting Person and the other purchasers named therein, the Reporting Person purchased 5,018 "Units" at a purchase price of $15.00 per Unit. Each Unit consisted of (i) one share of Series C Convertible Preferred Stock convertible into 10 shares of common stock and (ii) a warrant to purchase one share of Common Stock, which warrant is exercisable until April 8, 2014. The Reporting Person exchanged these securities for 93,786 shares of the company's common stock with a value of $0.8025 per share and warrants to purchase 46,894 shares of the company's common stock at an exercise price of $0.74 per share.
(3)	The shares acquired are the result of a 5% stock dividend on Pressure BioSciences, Inc. Series C Convertible Preferred Stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.